Hospira Blocks Sandoz's Generic Precedex

Law360, New York (May 1, 2012, 6:05 PM EDT) -- One of two patents asserted in Hospira Inc's. suit over Sandoz Inc.'s bid for approval of a generic version of the sedative Precedex is valid, and Sandoz is barred from selling the proposed generic until that patent expires in July 2013, a New Jersey federal judge said Monday.

However, the other patent-in-suit, which doesn't expire until March 2019, is invalid as obvious, U.S. District Judge Mary L. Cooper held. Though an opinion laying out the court's rationale remained sealed as of Tuesday afternoon, a two-page order...
To view the full article, register now.